GLPwatch
SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.
Med · 2025
Last updated 2026-05-28A clinical trial called SOUL found that oral semaglutide, a GLP-1 drug, reduced major heart-related events by 14% in people with type 2 diabetes. This benefit was similar to earlier injectable versions of semaglutide, showing that the medication works regardless of how it is taken.
AI summary of the abstract below.
| Journal | Med, 2025 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Semaglutide's evolution from weekly injections to an SNAC-enabled tablet preserved its metabolic and cardiovascular efficacy. Large injectable CVOTs have demonstrated robust cardioprotection, and the SOUL trial now shows a 14% reduction in major adverse cardiovascular events with the oral formulation. These data confirm formulation-independent benefit, positioning oral semaglutide as the only cardioprotective, non-injectable, GLP-1RA for high-risk type 2 diabetes.
Verbatim abstract via PubMed 40782670 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.